Wedbush Weighs in on Apellis Pharmaceuticals, Inc.’s FY2025 Earnings (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Research analysts at Wedbush cut their FY2025 earnings estimates for shares of Apellis Pharmaceuticals in a note issued to investors on Wednesday, April 17th. Wedbush analyst L. Chico now expects that the company will earn $2.23 per share for the year, down from their prior estimate of $2.24. Wedbush has a “Neutral” rating and a $57.00 price objective on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.33) per share.

Several other research firms have also commented on APLS. Jefferies Financial Group raised shares of Apellis Pharmaceuticals from a “hold” rating to a “buy” rating and increased their target price for the company from $68.00 to $80.00 in a report on Monday, February 5th. JPMorgan Chase & Co. lifted their target price on shares of Apellis Pharmaceuticals from $78.00 to $79.00 and gave the stock an “overweight” rating in a report on Wednesday, March 6th. The Goldman Sachs Group lifted their target price on shares of Apellis Pharmaceuticals from $65.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, January 9th. Needham & Company LLC reissued a “buy” rating and set a $85.00 price objective on shares of Apellis Pharmaceuticals in a report on Tuesday, April 9th. Finally, Oppenheimer boosted their price objective on shares of Apellis Pharmaceuticals from $75.00 to $79.00 and gave the company an “outperform” rating in a report on Tuesday, January 30th. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $77.93.

Apellis Pharmaceuticals Stock Performance

NASDAQ APLS opened at $47.51 on Thursday. Apellis Pharmaceuticals has a 1 year low of $19.83 and a 1 year high of $94.75. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.10 and a quick ratio of 2.50. The stock has a market capitalization of $5.73 billion, a PE ratio of -10.60 and a beta of 0.88. The company’s 50 day simple moving average is $60.13 and its two-hundred day simple moving average is $56.97.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($0.73) EPS for the quarter, hitting the consensus estimate of ($0.73). Apellis Pharmaceuticals had a negative net margin of 133.34% and a negative return on equity of 178.60%. The company had revenue of $146.38 million during the quarter, compared to the consensus estimate of $143.34 million. During the same period last year, the firm earned ($1.50) EPS. Apellis Pharmaceuticals’s revenue for the quarter was up 545.9% on a year-over-year basis.

Institutional Investors Weigh In On Apellis Pharmaceuticals

A number of hedge funds have recently bought and sold shares of APLS. Bank of New York Mellon Corp raised its stake in Apellis Pharmaceuticals by 5.8% during the first quarter. Bank of New York Mellon Corp now owns 315,480 shares of the company’s stock valued at $16,029,000 after purchasing an additional 17,287 shares in the last quarter. American Century Companies Inc. purchased a new stake in shares of Apellis Pharmaceuticals in the first quarter valued at $820,000. US Bancorp DE raised its stake in shares of Apellis Pharmaceuticals by 391.2% in the first quarter. US Bancorp DE now owns 1,110 shares of the company’s stock valued at $56,000 after acquiring an additional 884 shares during the period. MetLife Investment Management LLC raised its stake in shares of Apellis Pharmaceuticals by 67.0% in the first quarter. MetLife Investment Management LLC now owns 41,293 shares of the company’s stock valued at $2,098,000 after acquiring an additional 16,567 shares during the period. Finally, Rhumbline Advisers raised its stake in shares of Apellis Pharmaceuticals by 5.2% in the first quarter. Rhumbline Advisers now owns 77,764 shares of the company’s stock valued at $3,951,000 after acquiring an additional 3,835 shares during the period. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Insiders Place Their Bets

In other news, insider Pascal Deschatelets sold 69,107 shares of the business’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $54.17, for a total value of $3,743,526.19. Following the transaction, the insider now owns 1,115,983 shares of the company’s stock, valued at $60,452,799.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, CEO Cedric Francois sold 250,000 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $64.11, for a total transaction of $16,027,500.00. Following the sale, the chief executive officer now owns 313,662 shares of the company’s stock, valued at $20,108,870.82. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Pascal Deschatelets sold 69,107 shares of the company’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $54.17, for a total transaction of $3,743,526.19. Following the sale, the insider now directly owns 1,115,983 shares in the company, valued at approximately $60,452,799.11. The disclosure for this sale can be found here. Insiders sold a total of 406,651 shares of company stock worth $25,130,257 over the last three months. 7.50% of the stock is currently owned by company insiders.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).